Please login to the form below

Not currently logged in
Email:
Password:

PharmApprove appoints Solvay's Coos De Graaf

He will to lead the agency's new European office

PharmApprove Coos De GraafRegulatory and scientific communications firm PharmApprove has opened a European office and appointed Coos De Graaf to lead its operations in the region.  

De Graaf, who joins as principal for commercial operations in Europe, has more than 30 years' experience in pharma, including numerous roles in senior management.  

He moves to PharmApprove, a New Jersey, US-headquartered division of Taft and Partners, from Solvay Pharmaceuticals, where he led various functions, including global compliance and clinical and commercial development.  

The opening of a European office signals, said PharmApprove, “a new push towards expanded services and geographic markets”. Under De Graaf's leadership, PharmApprove will continue to support clients preparing to bring new therapeutic agents and devices before assessment agencies.  

"PharmApprove has established client experience in Europe, but adding a leader of Coos De Graaf's calibre positions us extremely well to continue growing to serve our clients globally," said PharmApprove president Laurie Smaldone.   

"In addition we are excited to announce expanded services building upon our success in supporting product approvals to include market access communication support."   

Along with expanding its services, PharmApprove has outlined three key areas of focus: advisory committee preparation, regulatory communication and market access communications support.

24th December 2013

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics